NYSE
$171.28▼ 0.15%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $265.66BShares out 15.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
38- 3d agoPre-market26.10.22 20:106-KKey event#●●●#●●●#●●●
ASTRAZENECA PLCBullish
AstraZeneca's Alexion has received accelerated approval from the US FDA for Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). This approval is based on interim analysis results from the Phase III I CAN trial, which demonstrated a 43.4% reduction in proteinuria compared to placebo at 34 weeks.…more
$171.28-0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8Pre-market26.10.08 20:124Ownership
ASTRAZENECA PLC
AstraZeneca PLC insider Sharma Mani filed a Form 4 report on October 8, 2026, regarding changes in beneficial ownership of securities as of October 6, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$171.28-0.15%vs prev closeView filingShare - 10.5Pre-market26.10.05 20:356-KKey event
ASTRAZENECA PLC
AstraZeneca has successfully completed a $2 billion equity investment in Summit Therapeutics. This investment will accelerate the development of ivonescimab, a first-in-class bispecific antibody, and expand clinical research across various tumor types in collaboration with Daiichi Sankyo.…more
$171.28-0.15%vs prev closeView filingShare
37 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoRegular26.10.23 02:08#●●●#●●●
AstraZeneca Receives FDA Accelerated Approval for Rare Kidney Disease Drug…more
AstraZeneca's Ultomiris has received FDA accelerated approval for reducing proteinuria in adults with IgA nephropathy. Continued marketing authorization remains contingent on verifying clinical benefits in an ongoing Phase 3 trial.…more
$171.28-0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoPre-market26.10.22 21:11
●●●●●●●● ●●●●● ●●●●●●
AstraZeneca has officially launched ZEGFROVY in the U.S. for the treatment of adults with EGFR exon 20 insertion-mutated non-small cell lung cancer. This launch expands the company's oncology portfolio by providing a new targeted therapy option for patients with limited treatment alternatives.…more
$171.28-0.15%vs prev closeShareBenzinga - 3d agoOvernight26.10.22 15:49
●●●●●●●● ●●●●● ●●●●●●
AstraZeneca's Alexion has received FDA accelerated approval for Ultomiris as a treatment for adults with IgA nephropathy. Phase III trial data demonstrated a 43.4% reduction in proteinuria compared to placebo at 34 weeks.…more
$171.28-0.15%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report